Identifying beneficial gastric cancer patient on prognosis after treating with perioperative or postoperative-only chemotherapy: a single-center real-world study.

World J Surg Oncol · 2025 · PMC12051334 · PMID 40320534

Europe PMC DOI

hedged sentence

0.1800

closest p · 3.6× alpha

0.1800

boldest claim

The sentences

showed a trendP = 0.18not close (p > 0.1)

Comparison of survival after propensity score matching and neoadjuvant chemotherapy prognostic factors The adjuvant XELOX group showed a trend toward better survival compared to the perioperative SOX group (95% CI = 0.388–1.205, P = 0.18).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.